Skip to main content
European Commission logo
polski polski
CORDIS - Wyniki badań wspieranych przez UE
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary
Zawartość zarchiwizowana w dniu 2024-06-18

New approach to treatment of the blinding disease Retinopathy of Prematurity (ROP)

Cel

The overall objective is to develop a novel preventative intervention for the blinding disease retinopathy of prematurity (ROP) and other complications of prematurity. The PREVENTROP consortium proposes to conduct preclinical studies (pharmacological, pharmacodynamics, pharmacokinetics and toxicological) in models and/or clinical studies (including phase III clinical trial) of an EU designated orphan medicinal product. This orphan medicinal product has been granted the EU orphan designation.
We have completed both a Phase I study and the first section of the Phase II study administering the growth factor complex IGF-I/IGFBP-3 (Premiplex®) successfully to preterm infants in order to prevent ROP– a discovery that we have taken from bench to bedside.
Due to improved neonatal care, the survival of preterm babies has increased dramatically during the last decades. The downside of this improvement in survival rates is higher morbidity affecting these vulnerable infants. It should be emphasised that in a preterm infant any lasting morbidity will have a negative impact on the quality of life for a whole life span for both the individual and their families.
One of the most severe morbidities affecting these infants is retinopathy causing severe visual impairment and blindness.
Our research findings have rendered several editorials pointing at the hope of prevention strategies which if successful will change the paradigm for ROP and other morbidities in preterm infants.
There are three major impacts of the present proposal; (1) clinical availability of a new orphan designated drug product, Premiplex®, and (2) improved care of preterm infants and (3) a significant contribution towards the goal of the International Rare Disease Research Consortium (IRDiRC) by delivering one new therapy for a rare disease.

Zaproszenie do składania wniosków

FP7-HEALTH-2012-INNOVATION-1
Zobacz inne projekty w ramach tego zaproszenia

Koordynator

GOETEBORGS UNIVERSITET
Wkład UE
€ 906 314,41
Adres
VASAPARKEN
405 30 Goeteborg
Szwecja

Zobacz na mapie

Region
Södra Sverige Västsverige Västra Götalands län
Rodzaj działalności
Higher or Secondary Education Establishments
Kontakt administracyjny
Ellen Rydberg (Dr.)
Linki
Koszt całkowity
Brak danych

Uczestnicy (9)